Product Watch
All the latest product news and developments, December 2008
Please click on any of the headlines below to see the full story.
An antioxidant eye drop (OT-551, Othera) is being investigated to treat geographic atrophy in dry age-related macular degeneration (AMD).
GS-101, Gene Signal's experimental topical ophthalmic solution designed to prevent the rejection of corneal grafts, has entered Phase III trials.
STAAR Surgical has created the Collamer Accommodating Study Team (CAST), a group of seven ophthalmologists who will investigate the accommodative properties of STAAR's Collamer intraocular lens (IOL).
Novagali Pharma SA has withdrawn the EMEA centralized marketing authorization application for Vekacia (cyclosporin) 0.05% eye drops, which had been intended for the treatment of vernal keratoconjunctivitis (VKC).
The Phase I three-year feasibility study of the Argus II Retinal Implant for Retinitis Pigmentosa (RP) will be expanded to enrol more patients in Europe, according to an announcement from Second Sight Medical Products, the implant's manufacturer.
For up-to-date news and announcements, please check the
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.












































